A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer
- 1 November 1996
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 10 (5) , 504-521
- https://doi.org/10.2165/00019053-199610050-00008
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.Journal of Clinical Oncology, 1996
- Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.Journal of Clinical Oncology, 1995
- Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.Journal of Clinical Oncology, 1995
- A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.1994
- Determining Transition ProbabilitiesMedical Decision Making, 1994
- Efficacy and Cost-Effectiveness of Cancer Treatment: Rational Allocation of Resources Based on Decision AnalysisJNCI Journal of the National Cancer Institute, 1993
- Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.1992
- High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1992
- Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast CancerNew England Journal of Medicine, 1991
- The Use of Female Spouse Proxies in Common Symptom ReportingMedical Care, 1989